Clinical Research Papers:
Tyrosine-protein phosphatase non-receptor type 12 expression is a good prognostic factor in resectable non-small cell lung cancer
Metrics: PDF 1635 views | HTML 2265 views | ?
Xun Cao1,*, Yan-Zhen Chen1,*, Ruo-Zhen Luo1,2, Lin Zhang1,3, Song-Liang Zhang1,5, Jun Zeng1,5, Yu-Chuan Jiang1,5, Yu-Jing Han1,4 and Zhe-Sheng Wen1,5
1 Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou, Guangdong, China
2 Department of Pathology, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, China
3 Department of Clinical Laboratory, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, China
4 Department of Preclinical Medicines, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, China
5 Department of Thoracic Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, China
* These authors contribute equally to this work
Zhe-Sheng Wen, email:
Keywords: non-small cell lung cancer, tyrosine-protein phosphatase non-receptor type 12, survival, prognosis
Received: January 06, 2015 Accepted: February 19, 2015 Published: March 14, 2015
Tyrosine-protein phosphatase non-receptor type 12 (PTPN12) has been considered to be a tumor suppressor in human cancer, but its clinical and prognostic significance in non-small cell lung cancer (NSCLC) has not been well elucidated.
A retrospective analysis of 215 patients with surgically resected NSCLCs from Sun Yat-Sen University Cancer Center between April 2002 and March 2005 was performed using immunohistochemistry and Western Blot to analyze PTPN12 expression. The association between PTPN12 expression and patient survival was investigated.
Western Blots showed that the expression level of PTPN12 were higher in normal paracancerous lung tissues than in NSCLC tissues. High PTPN12 expression was less common in the presence than in the absence of visceral pleural invasion (p=0.038). Patients with PTPN12-high tumors had a longer disease-free survival (DFS) (P<0.001) and overall survival (OS) (p<0.001), especially for those with non-squamous cell carcinoma (non-SCC) (DFS, p<0.001; OS, p<0.001). Multivariate analysis confirmed that PTPN12 positivity was associated with increased survival duration (DFS, p<0.001; OS, p<0.001), independent of prognostic indicator.
High PTPN12 expressive levels are associated with favorable survival duration in patients with NSCLC, especially those with non-SCC. Our study suggests that PTPN12 expression is a valuable prognostic biomarker for NSCLC patients.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.